A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
Latest Information Update: 10 Jan 2022
At a glance
- Drugs Posdinemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 23 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 16 May 2019 Planned number of patients changed from 80 to 70.